Key result
A kinetic-pharmacodynamic model demonstrated that a 300 mg subcutaneous dose of inclisiran every 6 months achieves rapid and sustained reductions in PCSK9 and LDL-C levels.
Why the study?
A kinetic-pharmacodynamic model was needed to characterize inclisiran's dose-related LDL-C lowering effects and evaluate the impact of intrinsic and extrinsic factors.
Does inclisiran 300 mg s.c. every 6 months provide sustained LDL-C reduction in patients with hypercholesterolemia?
Does inclisiran 300 mg s.c. every 6 months provide sustained LDL-C reduction in patients with hypercholesterolemia?
A kinetic-pharmacodynamic model confirms that inclisiran 300 mg s.c. every 6 months provides rapid and sustained LDL-C lowering despite a short plasma half-life.
Supports 6-month inclisiran dosing exploration; hypothesis-generating and requires randomized confirmation before practice change.
Inclisiran is a novel N-acetylgalactosamine (GalNAc) conjugated small-interfering ribonucleic acid (siRNA) therapy designed to specifically target proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA in the liver for the treatment of hypercholesterolemia. Inclisiran's GalNAc attachment results in a rapid uptake into the liver, and thus a short plasma half-life, but long duration of effects on PCSK9 inhibition and low-density lipoprotein cholesterol (LDL-C) lowering. The effects on PCSK9 inhibition and consequent LDL-C reduction are sustained for more than 6 months following a single subcutaneous (s.c.) dose, despite inclisiran being detectable in the plasma only for up to 48 hours. A kinetic-pharmacodynamic (K-PD) model was developed to characterize inclisiran's dose-related LDL-C lowering effects and to evaluate the impact of intrinsic and extrinsic factors on LDL-C lowering. To accommodate the long duration of action, the K-PD model incorporated an effect compartment which represents the liver. Inclisiran concentration in the liver leads to decreased production of the PCSK9 protein and allow recycling of more LDL-C receptors on the hepatocyte cell surface, which results in a reduction of circulating LDL-C. The analysis of covariates identified PCSK9 and LDL-C baseline levels as important factors for the effects of LDL-C lowering. Observations and modeling and simulation results demonstrated that PCSK9 and LDL-C reductions are achieved rapidly after dosing and sustained when patients are treated with a 300 mg s.c. dose once every 6 months.
No takes yet. Share an insight, caveat, or question.
Gosselin et al. (2022) studied Hypercholesterolemia. Inclisiran was evaluated on PCSK9 and LDL-C reductions. A kinetic-pharmacodynamic model demonstrated that a 300 mg subcutaneous dose of inclisiran every 6 months achieves rapid and sustained reductions in PCSK9 and LDL-C levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: